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ABSTRACT 
Software systems are becoming increasingly complex. Within  
safety critical domains such as medical device software, this 
increasing complexity is placing growing demands on 
manufacturers who must ensure their software not only meets 
functional requirements but is also safe and reliable. However, the 
Food and Drugs Administration who regulate medical device 
software in the United States report a significant increase in 
recalls between years 2003 and 2012 and have cited software 
difficulties as one of the frequent causes of recalls. Furthermore a 
recent analysis of traceability documentation submitted to the 
Administration has revealed that the traceability data was 
incomplete, incorrect, and conflicting in many cases. This is 
problematic as traceability plays an important role in the 
development of safe and reliable software. In this paper we 
present the validation, through industry trial, of a traceability 
assessment and implementation framework which we have 
developed to assist medical device organizations implement 
traceability in an efficient and regulatory compliant manner. Our 
findings show that implementation of the framework within two 
organizations improved their traceability process and that both 
organizations found the framework to be both useful and usable. 
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1. INTRODUCTION 
Traceability, which is the ability to establish and use the links (or 
traces) between source artefacts and target artefacts [7].   
 
Traceability is important as developers need to ensure that their 
software conforms to customer expectations, functional and 
regulatory requirements. Additionally, traceability is important for 
impact analysis as it assists developers to visualize how a change 
in any component can affect the software system. Therefore an 
effective traceability process supports the development of quality 
software and reduces the possibility of delays, recalls, or even 
complete project failures. Despite this traceability is problematic 
as ‘most existing software systems lack explicit traceability links 
between artefacts’ [8].  
Organizations that produce safety critical software must ensure 
their software is safe, reliable and available. Safety critical 
software can be described as software, which if fails could cause 
damage to the environment, injury or death [22]. Within the safety 
critical medical device domain, medical devices must frequently 
interface with other equipment, connect to hospital and laboratory 
information systems, and work in high-stress situations. The 
increased demands on such devices has resulted in increased 
software complexity and has created formidable development 
challenges for their manufacturers [13]. A medical device can be 
described as any article intended for use in the diagnosis, care, 
treatment or prevention of disease that does not achieve its 
intended purpose by medicines [6]. A recent report by the United 
States Food and Drugs Administration (FDA) finds that the 
annual number of medical device recalls increased by 97 percent 
(from 600 to 1200) between years 2003 and 2012 and lists 
software difficulties as one of the most frequent causes of recall 
[3]. An analysis of medical device recalls in the EU reports 
similar figures to that of the United States [2], indicating a 
growing and significant problem. As in other domains, traceability 
implementation within the medical device domain is challenging 
and has been highlighted by a recent analysis of the traceability 
documents submitted to regulators in the United States as part of 
the medical device approval process. This analysis has revealed 
that the traceability data was incomplete, incorrect, and 
conflicting in many cases [1]. 
To determine the challenges to implementing traceability 
effectively, the authors conducted a literature review in addition 
to interviewing two medical device organizations [14, 17]. As a 
result a number of challenges were identified including a lack of 
guidance on what traceability to implement and how to implement 
it.  To assist medical device organizations overcome this 
challenge the authors have developed a traceability assessment 
and implementation framework (TAIF). The framework consists 
of a traceability assessment model (TAM) and a traceability 
roadmap (TR). The TAM identifies any gaps in an organizations 
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implementation of traceability best practices [18] and/or medical 
device standards’ traceability requirements[19], and the TR 
provides the pathway for an organization to plug those gaps. An 
initial validation of the TAIF was completed through expert 
review [15, 16]. Further validation of the model has been 
completed through its implementation in two medical device 
organizations. In this paper we present the results of that 
implementation and evaluate the ability of the TAIF to assist 
medical device software organizations implement effective 
traceability and put them on the path to regulatory compliance.  
The remainder of this paper is structured as follows: Section 2, 
outlines current assessment models’ relationship to traceability. 
Section 3 outlines the methodology used to evaluate the roadmap 
while Section 4 presents the results of the evaluation. Section 5 
provides for a discussion of the results while Section 6 concludes 
the paper. 
2. RELATED WORK 
A literature review was conducted by the authors to determine 
what other traceability assessment models or traceability 
roadmaps were available in the general, safety critical or medical 
device domains. 
2.1 Roadmaps 
 A Framework for Requirements Traceability [12] has been 
proposed which provides guidelines to assist with implementing 
traceability. This framework advocates the use of ‘Value Based 
Requirements Tracing’ which may not be an option if full tracing 
is a requirement of the customer or the medical device 
development process standards. Additionally this framework does 
not fulfil the requirements of a traceability implementation 
roadmap as defined in the introduction to this paper. 
‘Software Traceability: A Roadmap’ [23] presents a roadmap of 
research and practices related to software traceability and identify 
issues that are still open for further research. While this paper 
does highlight barriers to implementing traceability (and areas for 
further research) it does not provide a traceability implementation 
roadmap. 
A number of medical device standards implementation roadmaps 
have been developed [4, 5]. These roadmaps provide a pathway 
for medical device organizations to implement particular medical 
device standards for risk management, usability design, and 
quality management. However these roadmaps only provide 
traceability requirements from any one standard and there is no 
detail on how these requirements might be achieved.  
2.2 Traceability Assessment 
To assist organizations to improve their traceability researchers 
have published work on the assessment of traceability. Med-trace 
[10] is a lightweight traceability assessment method (containing 8 
stages) to assist medical device organizations to improve their 
software development traceability process. However, this 
assessment method is ‘lightweight’ in nature (as described by the 
authors), does not assess any of the best practices for 
implementing traceability, and its development was not  based on 
any recognized international standard e.g. ISO 15504 [9]. 
An approach to automate the assessment of traceability has been 
presented  in response to ‘the gap between what is described by 
guidelines and what is implemented in practice’ [20]. This 
approach, which is not specific to any particular domain, involves 
automatically parsing project data to capture trace information. 
While this approach automatically assesses the standards’ 
requirements for traceability it does not assess the implementation 
of traceability best practices. 
There are a number of process assessment models which provide 
common frameworks for assessing software process capability. 
These models include  ISO/IEC 15504 SPICE, Automotive 
SPICE [14], SPICE 4 SPACE [15], and CMMI [21]. These 
frameworks assess processes such as the software design process, 
software construction process, software testing process etc. 
However, the frameworks do not include a dedicated traceability 
assessment process. The frameworks do include elements of 
traceability assessment but it is spread out across a lot of 
processes and the traceability requirements are sometimes difficult 
to interpret. 
3. INDUSTRY VALIDATION 
In order to meet the aim of this study which is the evaluation of 
the TAIF, a longitudinal study of two medical device 
organizations was performed over a six month period. For the 
study the Adept process appraisal method [11] was employed as it 
could provide a comprehensive assessment of an organizations’ 
traceability compliance without being too onerous in terms of 
resources that the organization need to provide.  
An initial assessment was conducted in both organisations using 
the TAM which highlighted areas for improvement. A findings 
report was delivered to the organisation along with the TR which 
provided a pathway for the organisations to improve their 
traceability. A follow up assessment conducted six months later 
(again using the TAM) indicated what improvements were made. 
Additionally, after this follow up assessment, two representatives 
from each organization were interviewed about their experience of 
using the TAIF and how beneficial they found it to be. The 
interviews were semi-structured in nature as this provided a means 
to address any issues or points that may arise during the interview 
that may not have been predicted during the generation of the 
questions. The interview questionnaire was divided into two main 
parts. Part A examined the value and usefulness of the assessment 
experience to the organization. Part B examined the usefulness 
and usability of the roadmap in implementing the 
recommendations that had resulted from the initial assessment. 
3.1 Participants 
Organization ‘A’ is a small medical device software company, 
founded in 2002, based in Ireland. The company has a total of ten 
employees which include one programmer, one software tester 
and one quality assurance person. The company produces medical 
device software with a software safety classification of B, 
meaning non-serious injury is possible. 
Organization ‘B’ is a small Product Development & Design 
Engineering company focused on the Medical Device and Life 
Science market and is based in Ireland. The company, which was 
formed in 2007, employs 14 individuals with skills in mechanical, 
hardware and software engineering. The company are a third party 
supplier of software to medical device companies and have 
recently been accredited with IEC 62304 certification. 
4. RESULTS 
The results of the initial traceability implementation assessment 
and follow up assessment are presented in section 4.1. Section 4.2 
presents the results of evaluating the assessment experience while 
section 4.3 presents the results of the roadmap evaluation. The 
data presented in section 5.1 was collected through document 
analysis and interviews as part of the Adept method while the data 
presented in section 5.2 and 5.3 was collected through interviews.  
4.1 Processes Assessment 
The results of the initial assessment and final assessment are 
presented in tabular format in Table 1 and for the purpose of 
clarity the results are also presented as percentages in Table 2. 
Table 1. Best Practices and Traceability Links 
Implementation- Initial and Final Assessment 
Initial 
Assess 
Best Practices and Trace Links Not 
Implemented 
Final 
Assess 
 Best Practices  
 Company policy on traceability  
 Traceability improvement communication method B 
 Traceability Information Model  
 Traceability standard operating procedure  
 Resources to implement traceability unavailable B 
 Appropriate techniques not deployed B 
 Risk Management Traceability Requirement  
 Link hazardous situation to software item B 
 Link software item to software cause  
B Link software cause to risk control measure B 
B Link RCM to risk control verification A,B 
B Link Hazard to assessment of residual risk B 
 SDLC Traceability Requirement  
B Link software req. to system req. and their source A,B 
 Link software req. to source code (where required)  
B Link soft. arch. design to soft. detailed design B 
B Link soft. detailed design to source code B 
B Link soft arch. design to test A,B 
B Link soft detailed design to test B 
B Link source code to test B 
 Change Management Traceability Requirement  
B Link change request to problem report A,B 
Table 1, presents the traceability best practices and traceability 
requirements that were not implemented by either organisation 
‘A’ or ‘B’ during the initial assessment (Column 1.) and during 
the final assessment (Column 3). For example, both organizations 
‘A’ and ‘B’ had no traceability improvement communication 
method in place at the initial assessment. However, at the final 
assessment organisation ‘B’ had met this requirement. This means 
that organisation ‘B’ implemented a traceability improvement 
communication method between the initial and the final 
assessments while organisation A had not. Table 2 indicates the 
percentage achievement of the outcomes for each process. For 
example, organisation ‘A’ had fully achieved three (or 75%) of 
the outcomes in the initial assessment and in the final assessment 
they had fully achieved all four outcomes (i.e. 100%). As 
indicated in Table 1 the purpose of this outcome is to implement 
traceability between each change request and the problem report 
ID from which it originated. The organization achieved this by 
adding a ‘source of change request’ section to their change control 
form. 
Table 2. Results of Initial Assessment and Final Assessment 
 Best Pract. SDLC Trac RM Trac CM Trac 
 Init. Final Init. Final Init. Final Init. Final 
Org. A 5% 5% 22% 44% 40% 53% 75% 100% 
Org. B 10% 41% 89% 89% 75% 88% 100% 100% 
The results indicate an improvement in all processes except for 
organization A’s Best Practice process which remained at 5% of 
full implementation and organization B’s SDLC process and CM 
process (which had already been 100% complete). 
4.2 Evaluation of the Assessment Experience 
To fully evaluate the TAIF it was necessary to appraise the 
participating organizations experience of undergoing the 
assessment. Therefore, questions were formulated to ascertain the 
participating organizations perspective with regard to the value 
and usefulness of the assessment to the organizations.  
Within the assessment, all questions asked the users to respond 
using a five point Likert scale. In some cases answers ranged from 
strongly disagree (1) to strongly agree (5), or very bad (1) to very 
good (5). Additionally, the organizations were asked to provide a 
rationale for their decision. 
4.2.1 Value of Assessment  
With regard to the value of the assessment, questions were asked 
during the final assessment to determine: 
a) The organization’s understanding of the assessment process 
and its results; 
b) The organization’s understanding of the purpose of the 
activities that took place as part of the assessment; 
c) The organization’s perspective on whether the assessment 
was worth the time and effort expended? 
d) The organization’s view on how good or bad the assessment 
results characterize their traceability strength or weaknesses. 
The results are presented in Figure 4. 
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Figure 4. Value of Assessment 
As an example, in response to a question on whether the 
assessment was worth the time and effort expended, organization 
‘A’ responded with a ‘4’ and provided the following rationale: 
“Our organization did not have the knowledge or the expertise 
required. The assessment identified many areas that current 
practice was lacking. Extensive knowledge and experience would 
be required to produce the quality of report provided by the 
assessment….very few people would have this” 
4.2.2 Usefulness of assessment 
To evaluate the usefulness of the assessment, questions were 
formulated to determine the organization’s viewpoints with 
regards to: 
a) How the assessment helped us better understand what needs 
to be improved with regards to traceability? 
b) If the assessment improved awareness, buy-in and support 
for traceability within our organization; 
c) If the assessment model provides real direction for long 
term traceability improvement? 
The results are presented in Figure 5. 
 
Figure 5. Usefulness of Assessment 
As an example, in response to a question on how much the 
assessment helped the organization better understand what needs 
to be traced, organization ‘B’ returned a ‘5’ and provided the 
following rationale: “We are definitely much more aware of what 
needs to be traced. Although we were aware that traceability was 
a requirement of the standards we obviously weren’t aware of 
how much was required. The assessment has highlighted our 
deficiencies and as we are a small organization everyone is now 
very aware”. 
4.3 Evaluation of the Roadmap 
To evaluate the roadmap, questions were formulated to determine 
the participating organization’s perspective of the roadmap with 
regard to its usefulness and usability. These questions assessed 
their agreement with: 
a) The overview section is easy to understand; 
b) The correctness of the order of implementation as depicted 
in Overview section; 
c) The roadmap is useful in practice; 
d) The roadmap is usable in practice; 
e) The roadmap provides sufficient guidance. 
The results are presented in Figure 6. 
 
 
Figure 6. Roadmap - Usefulness and Usability 
As an example, in response to a question on how much they 
agreed that the roadmap provides sufficient guidance on how to 
go about improving traceability, organization ‘B’ scored this 
category with a ‘5’ and provided the following rationale: “The 
roadmap is comprehensive. It explains what you have to do and is 
not difficult to comprehend.” 
In addition to the above, a number of questions were asked to 
determine the organization’s viewpoint with regard to any 
deficiency they have observed with the roadmap, any suggestions 
they have for improvement, or what they thought were the major 
benefits of the roadmap. Organization ‘A’ suggested that it might 
help if the best practices could be prioritized, with ‘Resources’ as 
first best practice. The major benefit of the roadmap as far as 
organization ‘A’ was concerned was that ‘it provided them with 
an expertise that was not available within the organization and 
that they do not believe many organizations would have such a 
wealth of knowledge on the subject’. The fact that the roadmap 
detailed all the medical device traceability requirements was a 
major benefit for organization ‘B’ as they felt that the standards 
can be difficult to interpret. As an example of the usefulness and 
usability of the roadmap organization ‘A’ stated that for the CM 
process they were easily able to link change request to problem 
report as “Method B in Appendix C of the roadmap clearly 
defined how we could easily do this simply by adding a source of 
change request section to the change request form”. 
5. DISCUSSION 
The inadequate implementation of the best practice process in 
both organizations is clearly evident in Table 1. Organization ‘A’ 
indicated that the reason for this was that they were simply 
unaware of the best practices and did not have any expertise in 
this area. Additionally, the reason that they showed no 
improvement in this area was that they focused their resources 
towards the other three processes for two reasons: the SDLC, RM 
and CM processes contained ‘regulatory requirements’ whereas 
the best practice process did not; their resources were particularly 
limited during this time period with some personnel leaving the 
organization and not yet been replaced. Organization ‘A’ has 
indicated that they wish to achieve 100% implementation across 
all four processes but with their very limited resources they were 
not able to indicate when this would happen. While the results 
from organization ‘B’ indicated a marked improvement in their 
implementation of the best practices process they are acutely 
aware that they still have significant work to do in this area. They 
have indicated that the reason why further improvement has not 
been achieved is one of resources. However, organization ‘B’ has 
set itself a goal of achieving 100% implementation across the four 
process areas and to this extent a new person has been hired with 
part of his remit being to work towards this goal.  
The results of the evaluation of the assessment experience have 
been very positive as indicated in Figures 4 and 5. Figure 4 point 
b indicates that organization ‘A’ could have had a better 
understanding of the purpose of the activities that took place 
during the assessment. While Step 2 of the Adept method requires 
the assessment process be explained to staff prior to the 
assessment, for future assessments a more detailed explanation of 
the process will be delivered at Step 2. However it is believed that 
this did not have any effect on the results of the assessment. 
Another area noted for improvement is that the assessment report 
could better characterize the organizations traceability strong 
points, with organization ‘A’ stating: “although the assessment 
did expose many areas that we are not covering in current TM 
template, we are compliant in some areas which maybe could be 
more evident in the report”. 
While the evaluation of the assessment process has highlighted 
areas for improvement, the lightweight nature of the assessment 
was noted as a major benefit with organization ‘B’ stating: “it was 
good that the assessment interviews were done in less than 1.5 
hours as time is a limited resource in this organization”. 
With regard to the evaluation of the roadmap and as depicted in 
Figure 6, organization ‘A’ neither agreed or disagreed that the 
overview section was easy to understand and suggested that some 
form of color-coding would improve it and make it visually more 
appealing. On reflection, the authors consider this to be a valid 
point and so the overview is amended to highlight the SDLC, CM 
and RM processes (in red) and also the adoption of the best 
practices (in blue) through these processes. Additionally, 
organization ‘A’ suggested that the ‘resource’ best practice should 
come first and that the best practices should be given a priority 
rating. However, textual information in the overview section 
indicates that an organization should decide at an organization 
level, or the project manager should decide at the project level 
which of the traceability best practices to implement. Factors 
which will influence these decisions will include the availability 
of resources and how highly regarded traceability is within the 
organization. Additionally, the roadmap recommends that the best 
practices are implemented in the order presented in the roadmap 
where possible. This order of implementation arose as a result of 
the roadmap validation through expert review.  
6. CONCLUSION 
The results of implementing the TAIF within two medical device 
organizations clearly indicate a significant improvement in almost 
all traceability processes within both organizations, although none 
of the processes improved to a level of 100% adherence, the 
overriding reason given for this is resource issues (mostly time) 
within the organizations. These resource issues are clearly outside 
the scope of the TAIF.  
An evaluation of the assessment experience and traceability 
roadmap clearly indicates that both organizations found them to 
be very useful, usable and generally providing an awareness, 
knowledge and expertise in traceability that they did not 
previously have. Additionally, both organizations considered that 
the assessment provided them with guidance and real direction for 
long term traceability improvement.  
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